Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A catalog of associations between rare coding variants and COVID-19 outcomes.

medRxiv : the preprint server for health sciences·2021
Same author

Genome-wide analysis in 756,646 individuals provides first genetic evidence that <i>ACE2</i> expression influences COVID-19 risk and yields genetic risk scores predictive of severe disease.

medRxiv : the preprint server for health sciences·2021
Same author

A novel mutation in MYCN gene causing congenital absence of the flexor pollicis longus tendon as an unusual presentation of Feingold syndrome 1.

Clinical dysmorphology·2020
Same author

Is stopping secondary prophylaxis safe in HIV-positive talaromycosis patients? Experience from Myanmar.

HIV medicine·2020
Same author

Androgenic effects on ventricular repolarization: A translational study from the international pharmacovigilance database to iPSC-cardiomyocytes.

Annales d'endocrinologie·2020
Same author

A non-exercise based V02max prediction using FRIEND dataset with a neural network.

Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference·2017
Same journal

Epcoritamab Step-Up Dosing Regimen Selection and Optimization Using Repeated Time-to-Event Modeling for Cytokine Release Syndrome Risk Mitigation.

Clinical pharmacology and therapeutics·2026
Same journal

From Executor to Orchestrator: The Pharmacology Scientist in the Age of Agentic AI.

Clinical pharmacology and therapeutics·2026
Same journal

The Future of Clinical Pharmacology: The Right Medicine at the Right Dose for Each Patient.

Clinical pharmacology and therapeutics·2026
Same journal

Effects of Trimethoprim on Three Previously Proposed Putative Biomarkers for OCT2/MATE-Mediated Renal Drug-Drug Interactions in Healthy Volunteers.

Clinical pharmacology and therapeutics·2026
Same journal

Clinical Characterization of Enzyme and Transporter Precipitants to Evaluate Drug-Drug Interactions for Orforglipron, a Small Molecule Glucagon-Like Peptide-1 Receptor Agonist.

Clinical pharmacology and therapeutics·2026
Same journal

Symposium Report: Stakeholders' Perspectives on Phase 1 Trials in Japanese Prior to Multi-Regional Clinical Trials and Future Pathways.

Clinical pharmacology and therapeutics·2026
See all related articles

Related Experiment Video

Updated: May 23, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Clopidogrel: a case for indication-specific pharmacogenetics.

J A Johnson1, D M Roden, L J Lesko

  • 1College of Pharmacy and Center for Pharmacogenomics, University of Florida, Gainesville, FL, USA. Johnson@cop.ufl.edu

Clinical Pharmacology and Therapeutics
|April 20, 2012
PubMed
Summary
This summary is machine-generated.

The CYP2C19*2 gene variant affects clopidogrel metabolism. Evidence shows this genotype impacts major adverse cardiovascular outcomes after percutaneous coronary intervention but not other clopidogrel uses.

Related Experiment Videos

Last Updated: May 23, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Area of Science:

  • Pharmacogenomics
  • Cardiovascular Medicine
  • Drug Metabolism

Background:

  • Clopidogrel is an antiplatelet medication crucial for preventing cardiovascular events.
  • The CYP2C19*2 loss-of-function allele reduces the conversion of clopidogrel to its active metabolite.
  • Previous meta-analyses yielded conflicting results regarding the impact of CYP2C19 genotype on clopidogrel efficacy.

Purpose of the Study:

  • To review and synthesize existing meta-analytic data on the association between CYP2C19 genotype and clopidogrel's clinical outcomes.
  • To clarify the specific impact of the CYP2C19*2 allele on cardiovascular events in different clinical contexts.

Main Methods:

  • Systematic review and meta-analysis of published studies.
  • Analysis of cardiovascular outcomes stratified by CYP2C19 genotype status.
  • Focus on major adverse cardiovascular events (MACE) following percutaneous coronary intervention (PCI) and other clopidogrel indications.

Main Results:

  • Evidence supports a differential effect of CYP2C19 genotype on protection from major adverse cardiovascular outcomes specifically after percutaneous coronary intervention (PCI).
  • The impact of CYP2C19 genotype on cardiovascular outcomes was not consistently supported for other indications of clopidogrel therapy.
  • Meta-analyses results vary depending on the specific studies included, highlighting the need for careful interpretation.

Conclusions:

  • The CYP2C19 genotype, particularly the *2 loss-of-function allele, significantly influences clopidogrel's effectiveness in preventing major adverse cardiovascular outcomes post-PCI.
  • The clinical significance of CYP2C19 genotype testing for clopidogrel therapy may be context-dependent, primarily relevant for patients undergoing PCI.
  • Further research may be warranted to refine genotype-guided antiplatelet therapy strategies.